What is DotBio?
DotBio is at the forefront of biopharmaceutical innovation, leveraging its proprietary DotBody technology to engineer advanced antibody therapies. The company's platform is built upon stabilized human VH domains, facilitating the rapid development of bi- and tri-specific antibodies, antibody-drug conjugates, and intracellular antibodies. This sophisticated approach positions DotBio as a key partner for biopharmaceutical clients seeking cutting-edge therapeutic solutions to address complex medical challenges.
How much funding has DotBio raised?
DotBio has raised a total of $5.6M across 1 funding round:
Other Financing Round
$5.6M
Other Financing Round (2023): $5.6M with participation from Gaorong Capital, Proxima Ventures, and AIM-HI Accelerator Fund
Key Investors in DotBio
Gaorong Capital
Gaorong Capital is an emerging venture capital firm with significant capital under management, focusing on seed and growth stage investments in the TMT sector. Their investor base includes successful entrepreneurs from major tech companies, providing valuable industry resources and perspectives.
Proxima Ventures
Proxima Ventures Ltd operates within the Investment Banking industry, based in Tel Aviv, Israel. The firm engages in investment activities, contributing to the financial landscape of its portfolio companies.
AIM-HI Accelerator Fund
AIM-HI Accelerator Fund is a non-profit organization dedicated to advancing cancer research by providing seed funding to early-stage oncology startups. They aim to bridge the gap between research and clinical application, fostering innovation in cancer therapies.
What's next for DotBio?
With the recent injection of major strategic capital, DotBio is well-positioned for significant growth and expansion. The company's focus on developing novel antibody therapies suggests a strategic move towards scaling its research and development capabilities, potentially targeting new therapeutic areas or advancing existing pipelines toward clinical trials. This enterprise-level funding indicates strong investor confidence in DotBio's technology and its potential to disrupt the biopharmaceutical landscape, paving the way for future commercialization and market penetration.
See full DotBio company page
